Nasdaq
$12.26▼ 1.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.57BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 9.3After-hours26.09.04 05:054Ownership#●●●
Generate Biomedicines, Inc.
Insider Frances Arnold of Generate Biomedicines, Inc. reported a change in beneficial ownership of securities effective September 1, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's equity holdings.…more
$12.26-1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:20144Ownership
Generate Biomedicines, Inc.
Insider Frances Arnold of Generate Biomedicines, Inc. has filed a Form 144 to report a proposed sale of securities. This filing indicates a planned divestment by an insider, and investors should monitor for any subsequent changes in their holdings.…more
$12.26-1.21%vs prev closeView filingShare - 9.1After-hours26.09.02 05:27144Ownership
Generate Biomedicines, Inc.
Insider Frances Arnold of Generate Biomedicines, Inc. filed an SEC Form 144 on September 1, 2026, to report a proposed sale of company shares. This filing formalizes the insider's plan to dispose of equity, indicating that these shares will be sold into the market.…more
$12.26-1.21%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:00#●●●#●●●
Generate Biomedicines to Participate in November Investor Conferences
Generate Biomedicines announced its participation in upcoming healthcare investor conferences scheduled for November. This is a routine corporate event announcement and does not provide new material financial information.…more
$12.26-1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Regular26.10.15 00:30
●●●●●●●● ●●●●● ●●●●●●
Generate Biomedicines has partnered with Zealand Pharma to develop AI-engineered protein therapies targeting obesity and metabolic diseases. The deal allows Generate to receive up to $1.2 billion in milestone payments and tiered royalties.…more
$12.26-1.21%vs prev closeShareBenzinga - 10.13After-hours26.10.14 05:34
●●●●●●●● ●●●●● ●●●●●●
Generate Biomedicines has entered a strategic collaboration with Zealand Pharma to develop multispecific protein therapeutics for metabolic diseases using generative AI. The deal includes a $30 million upfront payment and up to $1.2 billion in potential milestone payments plus royalties.…more
$12.26-1.21%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report